COVID-19 vaccine trial participant not officially diagnosed with transverse myelitis

COVID-19 vaccine trial participant not officially diagnosed with transverse myelitis


Pharmaceutical company AstraZeneca on Wednesday said the sick participant that prompted it to halt its coronavirus vaccine trial has not officially been diagnosed with transverse myelitis.

Multiple outlets reported that a woman was diagnosed with the rare neurological disorder during the UK-based drug giant’s third phase of vaccine testing.

But a spokesperson for the company on Wednesday told CNBC that while trial was paused, the woman hasn’t been officially diagnosed with the disorder. The reports had misinterpreted comments by AstraZeneca’s CEO, Pascal Soriot, during a private conference call with investors, the company insisted.

Trending: Joe Biden Attempts to Demonstrate His Reading and Math Skills at Michigan Rally

“He stated that there is no final diagnosis and that there will not be one until more tests are carried out,” AstraZeneca’s spokesperson said. “Those tests will be delivered to an independent safety committee that will review the event and establish a final diagnosis.”

The woman was hospitalized due to her illness but is recovering and could be discharged as soon as Wednesday, according to CNBC.

Continue reading

You Might Like

Do NOT follow this link or you will be banned from the site!